Literature DB >> 6140268

Regulation of the immune response by prostaglandins.

J S Goodwin, J Ceuppens.   

Abstract

Of all the arachidonic acid metabolites, only prostaglandin E (PGE) has been shown to have a clear role in the regulation of cellular and humoral immune responses. In cellular immune responses such as T cell proliferation, lymphokine production, and cytotoxicity, PGE usually acts as a feedback inhibitor of the response. This is also true of macrophage and natural killer cytotoxicity. In some instances PGE is responsible for cellular activation rather than inhibition. This is clearest in the control of humoral immunity, where PGE production is a necessary component in the generation of some type of T suppressor cells. Disturbances in immune function found in several human conditions and diseases have been linked to changes in PGE mediated immunoregulation. Either increased production of PGE or increased sensitivity to PGE results in depressed cellular immunity. Conversely drugs which inhibit PGE production act as stimulants of cellular immune function in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140268     DOI: 10.1007/bf00915791

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  213 in total

1.  Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins.

Authors:  C S Galasko; A Bennett
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

2.  Control of lymphokine secretion by prostaglandins.

Authors:  D Gordon; M A Bray; J Morley
Journal:  Nature       Date:  1976-07-29       Impact factor: 49.962

3.  Enhancement of carcinogenesis by prostaglandins in male albino Swiss mice.

Authors:  A Lupulescu
Journal:  J Natl Cancer Inst       Date:  1978-07       Impact factor: 13.506

4.  Inhibition of mitosis of lymphocytes from human adults by lymphocytes from human newborns.

Authors:  L B Olding; K Benirschke; M B Oldstone
Journal:  Clin Immunol Immunopathol       Date:  1974-09

5.  Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin.

Authors:  J S Goodwin; A D Bankhurst; S A Murphy; D S Selinger; R P Messner; R C Williams
Journal:  J Clin Lab Immunol       Date:  1978-11

6.  Strong suppression by mononuclear leukocytes from human newborns on maternal leukocytes: mediation by prostaglandins.

Authors:  S A Johnsen; L B Olding; N G Westberg; L Wilhelmsson
Journal:  Clin Immunol Immunopathol       Date:  1982-06

7.  Indomethacin-sensitive suppressor cells regulate the cell-mediated cytotoxic response to SV 40-induced tumor-associated antigens in mice.

Authors:  M Glaser
Journal:  Eur J Immunol       Date:  1980-07       Impact factor: 5.532

8.  Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis.

Authors:  H Offner; B Danneskiold-Samsøe; P Dore-Duffy
Journal:  Clin Immunol Immunopathol       Date:  1982-02

9.  Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid.

Authors:  M J Droller; D Gomolka
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

10.  Prolongation of murine skin allografts by prostaglandin E1.

Authors:  C B Anderson; B M Jaffee; R J Graff
Journal:  Transplantation       Date:  1977-05       Impact factor: 4.939

View more
  145 in total

Review 1.  Biological and clinical significance of lipids as modulators of immune system functions.

Authors:  Manuel A de Pablo; María A Puertollano; Gerardo Alvarez de Cienfuegos
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 2.  Control of humoral immune responses by arachidonic acid metabolites.

Authors:  T W Behrens; J S Goodwin
Journal:  Agents Actions       Date:  1989-01

Review 3.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

4.  Prostanoid release by macrophages at a distance from an inflammatory site.

Authors:  M Tissot; S Strzalko; A Thuret; J P Giroud
Journal:  Br J Exp Pathol       Date:  1989-10

5.  Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease.

Authors:  F Kuroki; M Iida; T Matsumoto; K Aoyagi; K Kanamoto; M Fujishima
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

6.  The metabolism of arachidonic acid to prostaglandin E2 in plerocercoids of Spirometra erinacei.

Authors:  T Fukushima; A Isobe; N Hojo; K Shiwaku; Y Yamane; M Torii
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

7.  Immunosuppression by seminal prostaglandins.

Authors:  A J Quayle; R W Kelly; T B Hargreave; K James
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

8.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

9.  Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages.

Authors:  W W Zhong; P A Burke; M E Drotar; S R Chavali; R A Forse
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

10.  Effect of recombinant human macrophage colony-stimulating factor 1 on immunopathology of experimental brucellosis in mice.

Authors:  A G Doyle; W J Halliday; C J Barnett; T L Dunn; D A Hume
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.